Bio-Rad Laboratories, Inc.
BIONYSEHealthcare● Active
$294.85
+$0.53(+0.18%)
Market Cap$8.0B
P/E Ratio—
52W High$343.12
52W Low$218.14
Bio-Rad Laboratories, Inc. (BIO) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
BIO · earnings · updated Jun 8, 2026
Latest Earnings
Q2 FY2026Report Date: Apr 30, 2026EPS Actual
$1.89
Est. $1.99 · -5.0%
Revenue
$0.59B
Est. $0.59B · +0.4%
Fiscal Period
Q2 FY2026
FY ends December
Report Date
Apr 30, 2026
After Market Close
▼ Miss EPS
BIO reports quarterly as a NYSE-listed Medical - Devices company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
—
Rev. $0.58B
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.—
Rev. Est.$0.58B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Jul 30, 2026 | $1.75 | — | — | — | $0.62B | — |
| ▼ Q2 FY2026 | Apr 30, 2026 | $1.99 | $1.89 | -5.0% | $0.59B | $0.59B | +0.4% |
| ▼ Q1 FY2026 | Feb 12, 2026 | $2.57 | $2.51 | -2.3% | $0.69B | $0.69B | +0.6% |
| ▼ Q4 FY2025 | Oct 29, 2025 | $2.30 | $2.26 | -1.7% | $0.65B | $0.69B | -6.0% |
| ▲ Q3 FY2025 | Jul 31, 2025 | $1.93 | $2.61 | +35.2% | $0.65B | $0.63B | +2.8% |
| ▲ Q2 FY2025 | May 1, 2025 | $1.73 | $2.54 | +46.8% | $0.59B | $0.57B | +2.1% |
| ▲ Q1 FY2025 | Feb 13, 2025 | $2.86 | $2.90 | +1.4% | $0.67B | $0.68B | -1.8% |
| ▲ Q4 FY2024 | Oct 30, 2024 | $1.28 | $2.01 | +57.0% | $0.65B | $0.68B | -4.6% |
Q3 FY2026
Jul 30, 2026
EPS Actual
—
EPS Est.
$1.75
EPS Surpr.
—
Revenue
—
Q2 FY2026
Apr 30, 2026Miss
EPS Actual
$1.89
EPS Est.
$1.99
EPS Surpr.
-5.0%
Revenue
$0.59B
Q1 FY2026
Feb 12, 2026Miss
EPS Actual
$2.51
EPS Est.
$2.57
EPS Surpr.
-2.3%
Revenue
$0.69B
Q4 FY2025
Oct 29, 2025Miss
EPS Actual
$2.26
EPS Est.
$2.30
EPS Surpr.
-1.7%
Revenue
$0.65B
Q3 FY2025
Jul 31, 2025Beat
EPS Actual
$2.61
EPS Est.
$1.93
EPS Surpr.
+35.2%
Revenue
$0.65B
Q2 FY2025
May 1, 2025Beat
EPS Actual
$2.54
EPS Est.
$1.73
EPS Surpr.
+46.8%
Revenue
$0.59B
Q1 FY2025
Feb 13, 2025Beat
EPS Actual
$2.90
EPS Est.
$2.86
EPS Surpr.
+1.4%
Revenue
$0.67B
Q4 FY2024
Oct 30, 2024Beat
EPS Actual
$2.01
EPS Est.
$1.28
EPS Surpr.
+57.0%
Revenue
$0.65B
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2028 | $3.26 | $3.28 | $3.31 | 1 |
| Q3 FY2028 | $3.04 | $3.06 | $3.08 | 1 |
| Q2 FY2028 | $2.91 | $2.93 | $2.95 | 1 |
| Q1 FY2028 | $3.42 | $3.44 | $3.47 | 1 |
| Q4 FY2027 | $2.72 | $2.74 | $2.76 | 1 |
| Q3 FY2027 | $2.53 | $2.55 | $2.57 | 1 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2028 | $0.8B | $0.8B | $0.8B | 1 |
| Q3 FY2028 | $0.7B | $0.7B | $0.7B | 1 |
| Q2 FY2028 | $0.7B | $0.7B | $0.7B | 1 |
| Q1 FY2028 | $0.6B | $0.6B | $0.7B | 1 |
| Q4 FY2027 | $0.7B | $0.7B | $0.7B | 1 |
| Q3 FY2027 | $0.7B | $0.7B | $0.7B | 1 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▼ Q2 FY2026 | Apr 30, 2026 | -5.0% | $275.15 | $280.12 | +1.81% |
| ▼ Q1 FY2026 | Feb 12, 2026 | -2.3% | $293.69 | $292.42 | -0.43% |
| ▼ Q4 FY2025 | Oct 29, 2025 | -1.7% | $330.42 | $319.47 | -3.31% |
| ▲ Q3 FY2025 | Jul 31, 2025 | +35.2% | $250.08 | $241.95 | -3.25% |
| ▲ Q2 FY2025 | May 1, 2025 | +46.8% | $244.08 | $240.43 | -1.50% |
| ▲ Q1 FY2025 | Feb 13, 2025 | +1.4% | $312.36 | $306.36 | -1.92% |
| ▲ Q4 FY2024 | Oct 30, 2024 | +57.0% | $331.64 | $330.58 | -0.32% |
| ▲ Q3 FY2024 | Aug 1, 2024 | +46.7% | $338.36 | $341.25 | +0.85% |
Q2 FY2026+1.81%
Report Date
Apr 30, 2026
EPS Beat/Miss
-5.0%
Price Before
$275.15
Price After
$280.12
Q1 FY2026-0.43%
Report Date
Feb 12, 2026
EPS Beat/Miss
-2.3%
Price Before
$293.69
Price After
$292.42
Q4 FY2025-3.31%
Report Date
Oct 29, 2025
EPS Beat/Miss
-1.7%
Price Before
$330.42
Price After
$319.47
Q3 FY2025-3.25%
Report Date
Jul 31, 2025
EPS Beat/Miss
+35.2%
Price Before
$250.08
Price After
$241.95
Q2 FY2025-1.50%
Report Date
May 1, 2025
EPS Beat/Miss
+46.8%
Price Before
$244.08
Price After
$240.43
Q1 FY2025-1.92%
Report Date
Feb 13, 2025
EPS Beat/Miss
+1.4%
Price Before
$312.36
Price After
$306.36
Q4 FY2024-0.32%
Report Date
Oct 30, 2024
EPS Beat/Miss
+57.0%
Price Before
$331.64
Price After
$330.58
Q3 FY2024+0.85%
Report Date
Aug 1, 2024
EPS Beat/Miss
+46.7%
Price Before
$338.36
Price After
$341.25
Avg Beat Reaction-1.23%
Avg Miss Reaction-0.64%
Beat Rate5 / 8 quarters
Largest Move-3.31% (Q4 FY2025)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: BIO ends December
Bio-Rad Laboratories, Inc. (BIO) most recently reported earnings on April 30, 2026 for Q2 FY2026, posting EPS of $1.89 — missing the analyst consensus of $1.99 by -5.0%. The next BIO earnings date is expected around September 1, 2026.
Each quarter, investors track BIO earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. BIO revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
BIO's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
BIO earnings · 5 questionsBio-Rad Laboratories, Inc.'s next earnings report is expected around September 1, 2026. BIO typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; BIO historically reports after market close (AMC).
BIO earnings datewhen is BIO earningsBIO next earnings datewhen does BIO report earningsBIO earnings calendar
▸ Source: FMP · Bio-Rad Laboratories, Inc. SEC filings · US GAAP · Bio-Rad Laboratories, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026